Stenocare (STENO.CO) Stock Analysis & AI Equity Report
Stenocare (STENO.CO) overview
Stenocare (STENO.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, Stenocare reported revenue of DKK 2.2m and operating profit of DKK -33.1m; the year-end share price was 0.73 DKK and market capitalisation was DKK 25.0m. Stenocare is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Stenocare's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Stenocare
Stenocare A/S is a Danish pharmaceutical company focused on prescription-based medical cannabis. It develops and markets cannabis products, and imports and distributes them to patients in Denmark and several other European markets, as well as Australia. The company has also been shifting away from cultivation toward a trading model centered on approved medical cannabis products.
Generate the Stenocare report
Stenocare is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Stenocare and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.